MedWatch http://medwatch.dk/ MedWatch da Copyright 2012, MedWatch Wed, 22 Mar 2017 13:36:45 GMT MedWatch - seneste nyt MedWatch - seneste nyt medwatch.dk 2017-03-22T13:36:45Z da Copyright 2012, MedWatch MedWatch http://medwatch.dk/mwimg/logo/main_logo.png http://medwatch.dk/ “You have to remember that investment is a long-term business” http://medwatch.dk/secure/Top_picks_in_english/article9450924.ece?utm_source=Feed&utm_medium=latest Although its asset value and net result both dipped significantly in 2016, the new CEO of Novo A/S, Kasim Kutay, is very optimistic on behalf of the company. The long-term trend looks good, he says, and the company is ready to increase investments and bridge the gap between two of its units. Top picks in English Wed, 22 Mar 2017 13:36:45 GMT http://medwatch.dk/secure/Top_picks_in_english/article9450924.ece?utm_source=Feed&utm_medium=latest BY MARTIN HAVTORN PETERSEN 2017-03-22T13:36:45Z true “We’ll be a meaningful player, even in the lung market" http://medwatch.dk/secure/Top_picks_in_english/article9445041.ece?utm_source=Feed&utm_medium=latest US-based pharma group Bristol-Myers Squibb has come under pressure in the field of immuno-oncology, but the company’s CFO believes they are still in a strong position, also in the all-important lung cancer niche. He is open to looking at external innovation in one particular area. Top picks in English Wed, 22 Mar 2017 13:14:56 GMT http://medwatch.dk/secure/Top_picks_in_english/article9445041.ece?utm_source=Feed&utm_medium=latest BY MARTIN HAVTORN PETERSEN 2017-03-22T13:14:56Z true Cytovac continues partner search http://medwatch.dk/secure/Top_picks_in_english/article9450631.ece?utm_source=Feed&utm_medium=latest The Danish biotech company Cytovac headed to the BIO-Europe conference in Barcelona hoping to attract potential partners to help it advance its lead asset. Top picks in English Wed, 22 Mar 2017 12:25:54 GMT http://medwatch.dk/secure/Top_picks_in_english/article9450631.ece?utm_source=Feed&utm_medium=latest BY STEFAN SINGH KAILAY 2017-03-22T12:25:54Z true Biotech and CRO outfit Gubra continues explosive growth http://medwatch.dk/secure/Top_picks_in_english/article9450305.ece?utm_source=Feed&utm_medium=latest Thanks to a successful gamble on one particular niche, Denmark’s Gubra has managed to quadruple its employee base in just a few years. The two-pronged business is set to expand significantly in the future. Top picks in English Wed, 22 Mar 2017 11:07:02 GMT http://medwatch.dk/secure/Top_picks_in_english/article9450305.ece?utm_source=Feed&utm_medium=latest BY STEFAN SINGH KAILAY 2017-03-22T11:07:02Z true Novo Nordisk jumps on the discount wagon http://medwatch.dk/secure/Top_picks_in_english/article9445241.ece?utm_source=Feed&utm_medium=latest Novo Nordisk’s US unit has struck a deal with CVS Health for a new savings program that will give some patients up to 80 percent reduction on some of the group’s insulin products. It thus looks like times are changing in the Denmark-based insulin giant. Top picks in English Tue, 21 Mar 2017 14:51:36 GMT http://medwatch.dk/secure/Top_picks_in_english/article9445241.ece?utm_source=Feed&utm_medium=latest BY MARTIN HAVTORN PETERSEN & STEFAN SINGH KAILAY 2017-03-21T14:51:36Z true Saniona gets go ahead for phase IIa trial in obesity disorder http://medwatch.dk/secure/Top_picks_in_english/article9448105.ece?utm_source=Feed&utm_medium=latest Danish biotech Saniona is ready to initiate phase II studies of its lead candidate in a rare disease that leads to obesity and type 2 diabetes. The company aims to add additional endpoints to the study. Top picks in English Tue, 21 Mar 2017 14:46:25 GMT http://medwatch.dk/secure/Top_picks_in_english/article9448105.ece?utm_source=Feed&utm_medium=latest BY LONNI LYNGE 2017-03-21T14:46:25Z true BioPorto targets prominent new board member http://medwatch.dk/secure/Top_picks_in_english/article9444836.ece?utm_source=Feed&utm_medium=latest Diagnostics company BioPorto proposes a prominent biotech profile and former CEO of the company Symphogen as a new member of its board of directors, to be officially elected at its general meeting in April. Top picks in English Mon, 20 Mar 2017 10:46:24 GMT http://medwatch.dk/secure/Top_picks_in_english/article9444836.ece?utm_source=Feed&utm_medium=latest BY ELIZABETH MØNSTED JOHANSEN 2017-03-20T10:46:24Z true Bavarian CFO eyes a double jackpot http://medwatch.dk/secure/Top_picks_in_english/article9432915.ece?utm_source=Feed&utm_medium=latest With just one approval of its small pox vaccine Imvamune in the US, Bavarian Nordic could create two new sources of revenue in the near future. Top picks in English Wed, 15 Mar 2017 20:11:17 GMT http://medwatch.dk/secure/Top_picks_in_english/article9432915.ece?utm_source=Feed&utm_medium=latest BY STEFAN SINGH KAILAY 2017-03-15T20:11:17Z true Three things needed for AI revolution, says Qualcomm President http://medwatch.dk/Top_picks_in_english/article9434190.ece?utm_source=Feed&utm_medium=latest Artificial intelligence will be a major game changer in digital health in coming years, says founder and President of health tech giant Qualcomm Life. But important steps still need to be taken before the full potential can be reached. Top picks in English Wed, 15 Mar 2017 14:56:16 GMT http://medwatch.dk/Top_picks_in_english/article9434190.ece?utm_source=Feed&utm_medium=latest BY ELIZABETH MØNSTED JOHANSEN 2017-03-15T14:56:16Z false Chemometec’s new growth engine could attract buyers http://medwatch.dk/secure/Top_picks_in_english/article9431226.ece?utm_source=Feed&utm_medium=latest Chemometec is banking big on a new analysis device, scheduled for a broad launch during 2017. If the product lives up to the company’s own expectations, it could have wide-reaching consequences for the medtech company, one analyst believes. Top picks in English Wed, 15 Mar 2017 14:39:47 GMT http://medwatch.dk/secure/Top_picks_in_english/article9431226.ece?utm_source=Feed&utm_medium=latest BY ELIZABETH MØNSTED JOHANSEN 2017-03-15T14:39:47Z true Novo Seeds: better than anything we could have imagined http://medwatch.dk/secure/Top_picks_in_english/article9434447.ece?utm_source=Feed&utm_medium=latest Novo Seeds, a major shareholder in Galecto Biotech, is thrilled with the recently published data on the biotech company’s lead candidate, which it struck a lucrative deal with Bristol-Myers Squibb for a few years back. Top picks in English Wed, 15 Mar 2017 14:34:44 GMT http://medwatch.dk/secure/Top_picks_in_english/article9434447.ece?utm_source=Feed&utm_medium=latest BY STEFAN SINGH KAILAY 2017-03-15T14:34:44Z true New technology could revolutionize medtech firm’s business http://medwatch.dk/secure/Top_picks_in_english/article9429627.ece?utm_source=Feed&utm_medium=latest Through the biggest project ever from Innovation Fund Denmark, researchers have developed an ultrasound scanning technology with the potential to transform the market. A medtech company involved in the project is now trying to figure out how to commercialize the invention. Top picks in English Tue, 14 Mar 2017 12:31:34 GMT http://medwatch.dk/secure/Top_picks_in_english/article9429627.ece?utm_source=Feed&utm_medium=latest BY LOUISE WENDT JENSEN 2017-03-14T12:31:34Z true BMS’ takeover decision looms after ”overwhelming” data from Galecto http://medwatch.dk/secure/Top_picks_in_english/article9428154.ece?utm_source=Feed&utm_medium=latest Galecto Biotech has presented “ground-breaking” data from a phase II study with a candidate it partnered with Bristol-Myers Squibb on back in 2014. The clock is now ticking for BMS, which has to decide whether or not to use an option to buy the Denmark-based biotech. Top picks in English Mon, 13 Mar 2017 14:50:12 GMT http://medwatch.dk/secure/Top_picks_in_english/article9428154.ece?utm_source=Feed&utm_medium=latest BY STEFAN SINGH KAILAY 2017-03-13T14:50:12Z true